NVNO

enVVeno Medical Corp

Add to Watchlist

Advanced Chart

4.600

-0.04(-0.862%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.7171

Open

4.700

VWAP

4.67

Vol

33.60K

Mkt Cap

89.31M

Low

4.5837

Amount

157.04K

EV/EBITDA(TTM)

Total Shares

13.33M

54.16M

EV/OCF(TTM)

P/S(TTM)

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.240

+9.09%

-0.280

-6.67%

-0.300

-14.29%

Estimates Revision

The market is revising No Change the revenue expectations for enVVeno Medical Corporation (NVNO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 27.42%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+27.42%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for enVVeno Medical Corp (NVNO.O) is -4.30, compared to its 5-year average forward P/E of -3.62. For a more detailed relative valuation and DCF analysis to assess enVVeno Medical Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.62

Current PE

-4.30

Overvalued PE

-2.01

Undervalued PE

-5.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

42.63

Current PS

60.82

Overvalued PS

105.97

Undervalued PS

-20.70